Cis Curon Iv Injection 55ml 5s

What it is used for: Anesthesia.

Indications as listed by the manufacturer: As an adjunct to general anaesthesia. To facilitate non-emergency endotracheal intubation . To provide skeletal muscle relaxation during surgery or mechanical ventilation.

How it works: Cisatracurium, a stereoisomer of atracurium, is an intermediate duration, non-depolarising benzylisoquinolinium skeletal muscle relaxant. Cisatracurium besylate binds to cholinergic receptors on the motor end-plate to antagonise the action of acetylcholine, resulting in a competitive block of neuromuscular transmission. This action is readily reversed by anticholinesterase agents such as neostigmine.

Active ingredient: Cis-atracurium Besylate.

Reported side effects: Cardiovascular : Bradycardia (0.4%), hypotension (0.2%), flushing (0.2%). Respiratory : Bronchospasm (0.2%). Dermatological: Rash (0.1%). Hypersensitivity : Very rarely : Severe anaphylactic reactions have been reported in patients receiving Cis-Curon Injection in conjunction with one or more anaesthetic agents.

Known drug interactions: Enflurane , isoflurane , halothane , ketamine , aminoglycosides , polymyxin , spectinomycin , tetracyclines , linomycin , clindamycin , propranolol calcium-channel blockers , lignocaine , procaineamide , quninidine , furosemide , thiazides , mannitol , acetazolamide , phenytoin , carbamazepine .

Dosage in Adults :Tracheal intubation. The recommended intubation dose of Cis-Curon Injection for adults is 0.15 mg/kg bodyweight. Dosage in Paediatric Patients ages 1 month to 12 years: Tracheal Intubation: As in adults, the recommended intubation dose of Cis-Curon Injection is 0.15 mg/kg bodyweight administered rapidly over 5 to 10 seconds. OR As directed by your physician .

Active ingredient: Cis-atracurium Besylate. Labelled strength: 2mg/ml.

Store in a refrigerator (2°C–8°C). Do not Freeze .

Manufactured by Cis Pharmaceuticals (Pvt) Ltd.. Country of origin: Turkey.